Posts

,

Visiting the CCR Expo? Come and see Mr Richards discuss the Aurora Lift

Cosmetic Courses at the CCR-EXPO

 

One of the highlights of the aesthetic industry calendar, the CCR Expo, is fast approaching. It takes place this year on 8th-9th October at London Olympia – and we’re delighted to say we’re exhibiting. 

Whatever stage you’re at in your aesthetic career, the CCR Expo (Clinical Cosmetic and Reconstructive Expo) is sure to have something of interest for you.

If you’ve been before, you’ll know it’s one of the most respected events of its kind in the industry, comprising two days of surgical and non-surgical conferences, workshops, Continuing Professional Development content and live demonstrations – with the vast majority being free to attend as well as CPD accredited.

If you’ve never been to the CCR Expo, or are new to the industry, we’d really recommend a visit. You’ll access valuable information and resources that will enhance your knowledge, sharpen your skills and help develop your career.

What can you expect at the CCR Expo?

This year, for the first time, the CCR Expo programme includes a useful new educational stream specifically for those who are planning on making the move into aesthetics.

“Getting Started in Aesthetics” runs on both the Thursday and Friday, and aims to guide you through the whole process of making the transition to facial aesthetics.

The masterclass will cover both how and why to make the move into aesthetics, as well as filling you in on the specific regulations and legal complications you need to be aware of.

But there’s plenty that will be of interest if you’re already established in the industry too.

A varied programme of free lectures, seminars, meetings and demos includes a Surgical & Non-Surgical Workshop, Non-Surgical Conference and an Allergan Injectables Masterclass.

Additional paid-for events include the BAAPS Annual Scientific Meeting and the Journal of Aesthetic Nursing Conference, as well as the application-only British Cosmetic Dermatology Group Expert Session.

Meet Cosmetic Courses at the CCR Expo

If you do decide to come along, be sure to swing by our stand and say hello. You’ll find us in the BAAPS area on Stand G50.

Cosmetic Courses: Photo showing aesthetic trainer Dr Olha Vorodukhina

Our Medical Director Mr Adrian Richards and our trainer, qualified dentist Dr Olha Vorodukhina (pictured), will both be there, and will be happy to help if you’d like any advice on training courses, treatment techniques or the practicalities of getting started in aesthetics and setting up your business.

Adrian will also be talking about his ‘Aurora Lift’ on both days. You can catch him on Thursday 8th at 12.40pm and again on Friday 9th at 2.30pm.

The Aurora Lift is the Botulinum toxin and filler technique we use in our advanced facial rejuvenation training at Cosmetic Courses, as well as with patients at our sister company Aurora Skin Clinics.

It’s based on the concept of an A-frame, and involves treating the ageing face by injecting Botox and facial fillers at strategic points on an imaginary ‘A’.

Treating several areas along this ‘A’ – the Glabella, Cheeks, Nasolabial Folds, Marionette Lines and Pre Jowl Salcus – allows us to more effectively counter the downward migration of facial volume to restore the youthful ‘inverted triangle’. (Find out more about the Aurora Lift.)

If you know the basic Botox and filler techniques but are interested in learning more advanced applications, Adrian’s talk will be well worth a visit. So we hope to see lots of you there!

If you’d like to come along to the CCR Expo, registration is still open and you can book. For more information on the Aurora Lift or Cosmetic Courses’ programme of aesthetic training courses, please feel free to contact the team on 01844 318745 or email [email protected].

/by
,

Allergan Vs Valeant – the takeover saga continues

Who knew a takeover bid in the pharma industry would be so thrilling? The battle between Allergan Vs Valeant is shaping up like an epic tennis match, with shot after shot screaming back over the net.

The last was from Valeant, who announced they were seeking to bypass Allergan’s board of Directors and take their hostile bid directly to shareholders.

But now Botox maker Allergan have hit a blistering return. To head off the $53 billion hostile takeover bid, the board are preparing a slew of measures – including taking on debt to buy back their own shares.

Also on the table is a plan to make acquisitions of its own (anything Valeant can do…), as well as a round of spending cuts to increase shareholder value, according to Chief Executive David Pyott.

The hope is that these measures will be enough to persuade shareholders that Allergan is better off going it alone.

It’s thought that Allergan will officially reveal their masterplan when they release their second-quarter results later this month. But even then it seems the battle won’t be over.

Valeant have hit back, saying they already have enough shareholders on side to call a meeting to try and replace Allergan board members with nominees who support their takeover bid. They need the support of shareholders who hold at least 25% of the company’s shares.

Financial Analyst Ronny Gal says that while it’s possible for Allergan to swing things in their favour, they will find it challenging.

“When I run my numbers, a buyback alone doesn’t quite cut it. A buyback plus another round of cost cuts, or the acceleration of the discussed cost savings, does.”

An acquisition could help them, according to Gal, but only if it increases their profits – and quickly. To win round short-term investors, he says, Allergan needs to deliver another $10 per share in 2015 or $11 per share in 2016.

Get comfortable. Allergan Vs Valeant is going to run and run…

/by
,

Valeant seeking to bypass Directors to ‘seal the deal’ for Botox maker Allergan

This is the story that just won’t go away. We recently wrote about Botox maker Allergan rejecting a takeover bid by Canadian pharmaceutical company Valeant. But it seems Valeant have rhino hide, and won’t be letting rejection put them off.

It’s been reported that the conglomerate will this week launch an exchange offer for Allergan Inc, which will allow them to bypass the board of Directors and take their hostile bid directly to shareholders.

Allergan has already rejected Valeant’s $53 billion offer, but the company’s largest shareholder, Pershing Square Capital Management, has indicated it will be seeking a special meeting later this year to change most of Allergan’s board.

To trigger the meeting, Pershing needs to ensure the support of 25% of Allergan’s shareholders – an increase of 15.3% on its own holding of 9.7%.

Despite the challenge ahead, Valeant’s Chief Financial Officer Howard Schiller is bullish about their chances of shoring up the support. He pointed out that more than 50% of Allergan’s shares have traded since news of Valeant’s offer first leaked out on 21st April.

Talking about the controversy surrounding their approach to Allergan, Valeant’s Chief Executive Officer Mike Pearson, said:

“Hostile is not our preferred approach. But this deal was so strategic and financially compelling that it really makes sense.”

It increasingly seems that it’s a question of when, not if, this deal will finally go ahead.

 

/by